1. Home
  2. MODD vs IMRN Comparison

MODD vs IMRN Comparison

Compare MODD & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modular Medical Inc.

MODD

Modular Medical Inc.

N/A

Current Price

$2.17

Market Cap

11.2M

Sector

Health Care

ML Signal

N/A

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.19

Market Cap

9.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MODD
IMRN
Founded
1998
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
9.4M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
MODD
IMRN
Price
$2.17
$1.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
150.6K
★ 3.5M
Earning Date
02-17-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.68
52 Week High
$6.16
$2.38

Technical Indicators

Market Signals
Indicator
MODD
IMRN
Relative Strength Index (RSI) 39.28 45.60
Support Level $0.28 $1.01
Resistance Level $2.49 $1.22
Average True Range (ATR) 0.29 0.13
MACD -0.06 -0.03
Stochastic Oscillator 7.53 3.90

Price Performance

Historical Comparison
MODD
IMRN

About MODD Modular Medical Inc.

Modular Medical Inc is a development stage medical device company which focuses on the design, development, marketing and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: